[go: up one dir, main page]

AR106131A1 - VECTORS OF THE FACTOR VIII OF ADENOASOCIATED VIRUSES, ASSOCIATED VIVIC PARTICLES AND THERAPEUTIC FORMULATIONS THAT INCLUDE THEM, METHOD - Google Patents

VECTORS OF THE FACTOR VIII OF ADENOASOCIATED VIRUSES, ASSOCIATED VIVIC PARTICLES AND THERAPEUTIC FORMULATIONS THAT INCLUDE THEM, METHOD

Info

Publication number
AR106131A1
AR106131A1 ARP160102912A ARP160102912A AR106131A1 AR 106131 A1 AR106131 A1 AR 106131A1 AR P160102912 A ARP160102912 A AR P160102912A AR P160102912 A ARP160102912 A AR P160102912A AR 106131 A1 AR106131 A1 AR 106131A1
Authority
AR
Argentina
Prior art keywords
vivic
adenoasociated
viruses
vectors
particles
Prior art date
Application number
ARP160102912A
Other languages
Spanish (es)
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of AR106131A1 publication Critical patent/AR106131A1/en

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

Reivindicación 1: Una formulación farmacéutica que comprende un virus de FVIII del VAA recombinante, un agente tamponador, un agente de isotonicidad, un agente de volumen y un tensioactivo. Reivindicación 2: La formulación farmacéutica de la reivindicación 1, donde el virus de FVIII del VAA recombinante es AAV5-FVIII-SQ.Claim 1: A pharmaceutical formulation comprising a recombinant VAA FVIII virus, a buffering agent, an isotonicity agent, a volume agent and a surfactant. Claim 2: The pharmaceutical formulation of claim 1, wherein the recombinant VAA FVIII virus is AAV5-FVIII-SQ.

ARP160102912A 2015-09-24 2016-09-23 VECTORS OF THE FACTOR VIII OF ADENOASOCIATED VIRUSES, ASSOCIATED VIVIC PARTICLES AND THERAPEUTIC FORMULATIONS THAT INCLUDE THEM, METHOD AR106131A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562232242P 2015-09-24 2015-09-24

Publications (1)

Publication Number Publication Date
AR106131A1 true AR106131A1 (en) 2017-12-13

Family

ID=60931769

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160102912A AR106131A1 (en) 2015-09-24 2016-09-23 VECTORS OF THE FACTOR VIII OF ADENOASOCIATED VIRUSES, ASSOCIATED VIVIC PARTICLES AND THERAPEUTIC FORMULATIONS THAT INCLUDE THEM, METHOD

Country Status (1)

Country Link
AR (1) AR106131A1 (en)

Similar Documents

Publication Publication Date Title
CL2019001433A1 (en) Modulators of the core protein of hepatitis b. (divisional request 201800684)
MX2018003306A (en) Stable anti-pd-1 antibody pharmaceutical preparation and application thereof in medicine.
CL2018000740A1 (en) Vectors of factor viii of adeno-associated virus, associated viral particles and therapeutic formulations comprising them
CY1124288T1 (en) CMV VACCINE
MX2023013140A (en) Vaccines against hepatitis b virus.
MX2017013590A (en) Delivery of surfactant soluble anti-dandruff agent.
EA201792500A1 (en) AAV-MEDIATED EXPRESSION OF ANTIBODIES AGAINST FLU AND METHODS OF THEIR USE
MX2018003388A (en) Farnesoid x receptor agonists and uses thereof.
MX2017007458A (en) Fgf21 derivatives and uses thereof.
PL3896064T3 (en) 4,6-DIAMINO-QUINOLINE-3-CARBONITRILE DERIVATIVES AS COT MODULATORS IN THE TREATMENT OF CROOHN'S DISEASE AND ULTRASPECTRUM COLITIS
CL2016002794A1 (en) Peptide vaccine comprising a mutant ras peptide and a chemotherapeutic agent
MX386234B (en) MALARIA VACCINE.
CL2016001918A1 (en) Heteroaryl amides as protein aggregation inhibitors
GT201700124A (en) FORMULATION OF GLARGINE / LIXISENATIDA INSULIN FIXED RELATIONSHIP
MX2022005372A (en) COMBINATIONS AND FIXED DOSE FORMULATIONS COMPRISING ETC-1002 AND ONE OR MORE STATINS.
PH12020500569A1 (en) Influenza virus vaccines and uses thereof
MX383330B (en) FLAVIVIRUS VIRUS TYPE PARTICLE.
BR112018015367A2 (en) nanofiber oromucosal carriers for therapeutic treatment
MX392182B (en) FIXED-DOSE COMBINATIONS AND FORMULATIONS COMPRISING 8-HYDROXY-2,2,14,14 TETRAMETHYLPENTADECANEDIOIC ACID (ETC1002) AND EZETIMIBE AND METHODS FOR TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE.
MX385447B (en) ANTIHYPERTENSIVE AGENT
TW201613557A (en) Stable aqueous recombinant protein formulations
TN2018000284A1 (en) Stable liquid gonadotropin formulation
MX2017016774A (en) THERAPEUTIC AGENT FOR FIBROSIS.
CY1125031T1 (en) METHOD FOR GENE THERAPY USING AAV-XBP1S/GFP VIRUS AND USE THEREOF IN THE PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
BR112017023425A2 (en) therapeutic combinations of antiviral and anti-inflammatory therapies

Legal Events

Date Code Title Description
FC Refusal